Flunitrazolam

opioid use, alcohol use, barbiturate use, GHB/GBL use, other benzodiazepine use

Co-ingestion with opioids, alcohol, barbiturates, GHB, or other benzodiazepines produces synergistic respiratory depression that can be fatal. Flunitrazolam was identified alongside acrylfentanyl in 5 of 11 STRIDA intoxication cases in Sweden. The combination suppresses brainstem respiratory drive through complementary mechanisms at doses that would be survivable for either drug class alone.

COPD, sleep apnea, other respiratory insufficiency

Individuals with chronic obstructive pulmonary disease, sleep apnea, or other conditions compromising respiratory reserve face elevated risk of benzodiazepine-induced respiratory failure. Flunitrazolam's high potency and sub-milligram dosing increase the margin-of-error risk in this population.

myasthenia gravis

Benzodiazepine-induced muscle relaxation may worsen muscle weakness in myasthenia gravis patients. This is a class-level inference with no flunitrazolam-specific evidence.

substance use disorder history, sedative use disorder, polysubstance use disorder

The high reinforcement potential and compulsive redosing pattern associated with high-potency, short-acting benzodiazepines elevates relapse and dose-escalation risk in individuals with a history of sedative or polysubstance use disorder. Flunitrazolam's amnestic properties further amplify redosing risk.

hepatic impairment, liver disease, cirrhosis

Flunitrazolam undergoes hepatic Phase I metabolism and an anomalous Phase II glucuronidation pathway — unlike most designer benzodiazepines, no individual UGT isoform can catalyze its glucuronidation independently (Pettersson Bergstrand et al. 2019). Hepatic impairment may disproportionately prolong elimination relative to other benzodiazepines.

pregnancy, breastfeeding

No flunitrazolam-specific reproductive toxicity data exist. General benzodiazepine class concerns include teratogenicity (cleft palate risk with first-trimester exposure), neonatal sedation, and neonatal withdrawal syndrome ('floppy infant syndrome'). Given the absence of substance-specific safety data and the compound's high potency, exposure during pregnancy should be avoided.